Egros Fabrice 4
4 · Syndax Pharmaceuticals Inc · Filed May 20, 2021
Insider Transaction Report
Form 4
Egros Fabrice
Director
Transactions
- Exercise/Conversion
Common Stock
2021-05-18$7.88/sh+1,683$13,262→ 29,609 total - Exercise/Conversion
Common Stock
2021-05-18$7.20/sh+11,926$85,867→ 27,926 total - Sale
Common Stock
2021-05-18$18.65/sh−11,926$222,398→ 17,683 total - Sale
Common Stock
2021-05-18$18.65/sh−1,683$31,385→ 16,000 total - Exercise/Conversion
Stock Options (Right to buy)
2021-05-18−1,683→ 0 totalExercise: $7.88Exp: 2029-06-10→ Common Stock (0 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2021-05-18−11,926→ 0 totalExercise: $7.20Exp: 2025-08-18→ Common Stock (0 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 93,317 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
- [F2]This option is fully vested.